Generalized arterial calcification of infancy
Learn about Generalized arterial calcification of infancy, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: Arteriopathia calcificans infantum; Diffuse arterial calcifying elastopathy of infancy; GACI; IIAC; Idiopathic infantile arterial calcification; Idiopathic obliterative arteriopathy and 3 more
Infantile calcifying arteriopathy; Medial coronary sclerosis of infancy; Occlusive infantile arteriopathy
The sources compiled here do not cover: diagnosis, treatment, prevention. Ask the treating doctor about these.
What it is, symptoms and effects
From: MedlinePlus Genetics, National Library of Medicine
Generalized arterial calcification of infancy (GACI) is a disorder affecting the circulatory system that becomes apparent before birth or within the first few months of life. It is characterized by abnormal accumulation of the mineral calcium (calcification) in the walls of the blood vessels that carry blood from the heart to the rest of the body (the arteries). This calcification often occurs along with thickening of the lining of the arterial walls (the intima). These changes lead to narrowing (stenosis) and stiffness of the arteries, which forces the heart to work harder to pump blood. As a result, heart failure may develop in affected individuals, with signs and symptoms including difficulty breathing, accumulation of fluid (edema) in the extremities, a bluish appearance of the skin or lips (cyanosis), severe high blood pressure (hypertension), and an enlarged heart (cardiomegaly).
People with GACI may also have calcification in other organs and tissues, particularly around the joints. In addition, they may have hearing loss or softening and weakening of the bones (rickets).
Some individuals with GACI also develop features similar to those of another disorder called pseudoxanthoma elasticum (PXE). PXE is characterized by the accumulation of calcium and other minerals (mineralization) in elastic fibers, which are a component of connective tissue. Connective tissue provides strength and flexibility to structures throughout the body. Features characteristic of PXE that also occur in GACI include yellowish bumps called papules on the underarms and other areas of skin that touch when a joint bends (flexor areas); and abnormalities called angioid streaks affecting tissue at the back of the eye, which can be detected during an eye examination.
As a result of the cardiovascular problems associated with GACI, individuals with this condition often do not survive past infancy, with death typically caused by a heart attack or stroke. However, affected individuals who survive their first six months, known as the critical period, can live into adolescence or early adulthood.
Causes and biological mechanisms
From: MedlinePlus Genetics, National Library of Medicine
In about two-thirds of cases, GACI is caused by mutations in the ENPP1 gene. This gene provides instructions for making a protein that helps break down a molecule called adenosine triphosphate (ATP), specifically when it is found outside the cell (extracellular). Extracellular ATP is quickly broken down into other molecules called adenosine monophosphate (AMP) and pyrophosphate. Pyrophosphate is important in controlling calcification and other mineralization in the body. Mutations in the ENPP1 gene are thought to result in reduced availability of pyrophosphate, leading to excessive calcification in the body and causing the signs and symptoms of GACI.
GACI can also be caused by mutations in the ABCC6 gene. This gene provides instructions for making a protein called MRP6, also known as the ABCC6 protein. This protein is found primarily in the liver and kidneys, with small amounts in other tissues such as the skin, stomach, blood vessels, and eyes.
MRP6 is thought to transport certain substances across the cell membrane; however, the substances have not been identified. Some studies suggest that the MRP6 protein stimulates the release of ATP from cells through an unknown mechanism, allowing it to be broken down into AMP and pyrophosphate and helping to control deposition of calcium and other minerals in the body as described above. Other studies suggest that a substance transported by MRP6 is involved in the breakdown of ATP. This unidentified substance is thought to help prevent mineralization of tissues.
Mutations in the ABCC6 gene lead to an absent or nonfunctional MRP6 protein. It is unclear how a lack of properly functioning MRP6 protein leads to GACI. This shortage may impair the release of ATP from cells. As a result, little pyrophosphate is produced, and calcium accumulates in the blood vessels and other tissues affected by GACI. Alternatively, a lack of functioning MRP6 may impair the transport of a substance that would normally prevent mineralization, leading to the abnormal accumulation of calcium characteristic of GACI.
Some people with GACI do not have mutations in the ENPP1 or ABCC6 gene. In these affected individuals, the cause of the disorder is unknown.
Inheritance and family implications
From: MedlinePlus Genetics, National Library of Medicine
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
How common is it?
From: MedlinePlus Genetics, National Library of Medicine
The prevalence of GACI has been estimated to be about 1 in 391,000. At least 200 affected individuals have been described in the medical literature.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Arterial calcification · Very frequent (99-80%)
- Pathological deposition of calcium salts in one or more arteries.
- Calcification of the aorta · Very frequent (99-80%)
- Calcification, that is, pathological deposition of calcium salts in the aorta.
- Generalized arterial calcification · Very frequent (99-80%)
- Calcification, that is, pathological deposition of calcium salts, affecting arteries distributed throughout the body.
- Hepatic calcification · Very frequent (99-80%)
- The presence of abnormal calcium deposition in the liver.
- Coronary artery calcification · Frequent (79-30%)
- An accumulation of calcium and phosphate in arteries with mineral deposits in the intimal or medial layer of the vessel wall in a coronary artery.
- Cyanosis · Frequent (79-30%)
- Bluish discoloration of the skin and mucosa due to poor circulation or inadequate oxygenation of arterial or capillary blood.
- Ectopic calcification · Frequent (79-30%)
- Deposition of calcium salts in a tissue or location in which calcification does not normally occur.
- Feeding difficulties · Frequent (79-30%)
- Impaired ability to eat related to problems gathering food and getting ready to suck, chew, or swallow it.
Other findings in the same source
From: Orphanet
Additional reported features include Fetal distress (Frequent (79-30%)); Hearing impairment (Frequent (79-30%)); Hypertension (Frequent (79-30%)); Left ventricular systolic dysfunction (Frequent (79-30%)); Medial calcification of large arteries (Frequent (79-30%)); Medial calcification of medium-sized arteries (Frequent (79-30%)); Medullary nephrocalcinosis (Frequent (79-30%)); Nephrocalcinosis (Frequent (79-30%)); Osteomalacia (Frequent (79-30%)); Periarticular calcification (Frequent (79-30%)). This is a selected summary, not a complete description of the condition.
Which doctor should you see?
The suggested department for discussing Generalized arterial calcification of infancy is Vascular Medicine, with a vascular specialist / vascular surgeon as the relevant type of clinician. General physician / Family Medicine; paediatrician for children. Referral depends on symptoms.
Additional services that may be relevant, depending on the findings, include: Clinical Genetics.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Which part of the circulation needs assessment?
- What changes in pain, swelling, colour or limb function require prompt reassessment?
- Would observation, a medical approach or a procedure be considered in this case?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Generalized arterial calcification of infancy. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
Vascular Medicine is not listed separately on The Doctor Index; the nearest speciality is cardiology. Every profile shows the doctor’s registration and what has been checked.
All vascular medicine conditions →
Sources
- MedlinePlus Genetics, National Library of Medicine — Generalized arterial calcification of infancy — Public-domain Genetics summary
- Orphanet — clinical features for ORPHA:51608 — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-0994.